Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

D van der Heijde, JCC Wei, M Dougados, P Mease… - The Lancet, 2018 - thelancet.com
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …
被引用次数：367 相关文章

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

COAST-V study group - The Lancet, 2018 - ohsu.elsevierpure.com
Background: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

D van der Heijde, JCC Wei… - Lancet (London …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …
[PDF] academia.edu

[PDF][PDF] Ixekizumab, an Interleukin-17A Antagonist in the Treatment of Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 …

D van der Heijde, JCC Wei, M Dougados, P Mease… - academia.edu
Background: Biologic disease modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis (r-axSpA), otherwise known as …

[引用][C] Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

D van der Heijde, WJ Cheng-Chung, M Dougados… - The Lancet, 2018 - elibrary.ru

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

D van der Heijde, JCC Wei, M Dougados, P Mease… - …, 2018 - scholarworks.bwise.kr
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

D van der Heijde, JCC Wei, M Dougados, P Mease… - LANCET, 2018 - biblio.ugent.be
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …
[PDF] universiteitleiden.nl

[PDF][PDF] Ixekizumab, an Interleukin-17A Antagonist in the Treatment of Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 …

D van der Heijde, JCC Wei, M Dougados, P Mease… - scholarlypublications …
Background: Biologic disease modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis (r-axSpA), otherwise known as …

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

COAST-V study group - The Lancet, 2018 - khu.elsevierpure.com
Background: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …

COAST-V study group - The Lancet, 2018 - cuk.elsevierpure.com
Background: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are
recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing …